License agreement leverages UCB’s expertise in antibody drug discovery to support Refold Therapeutics' ambition of providing better treatments for patients suffering from diseases caused by misfolded free light chain
LIVERPOOL, February 23rd, 2026: Refold Therapeutics, a start-up drug discovery company based in Liverpool, UK, today announced a global, exclusive license agreement granting Refold the rights to the development of UCB owned antibodies directed against misfolded free light chains. These disease-causing proteins are implicated in light chain amyloidosis (the most common form of systemic amyloid disease) and certain types of cancer.